Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

4 Nov 2011

Abstract excerpt

The polycomb repressive complex 2 (PRC2) is a highly conserved histone H3 lysine 27 methyltransferase that regulates the expression of developmental genes. Inactivating mutations of the catalytic component of PRC2, EZH2, are seen in myeloid disorders. We reasoned that the other 2 core PRC2 components, SUZ12 and EED, may also be mutational targets in these diseases, as well as associated factors such as JARID2....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22053108
DOI: 10.1182/blood-2011-07-367243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsPMID 22053108Read ↗

EZH2 in Myeloid Malignancies.Semantic proximity Read ↗

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.Semantic proximity Read ↗

Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.Semantic proximity Read ↗

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent mannerSemantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsSemantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.Semantic proximity Read ↗

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasmsSemantic proximity Read ↗

The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibitionSemantic proximity Read ↗

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read ↗

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.